C-[1-(Tetrahydro-pyran-4-yl)-piperidin-4-yl]-methylamine | 438056-67-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: C-[1-(Tetrahydro-pyran-4-yl)-piperidin-4-yl]-methylamine
• 英文别名: [1-(Oxan-4-yl)piperidin-4-yl]methanamine
• CAS: 438056-67-8
• 化学式: C₁₁H₂₂N₂O
• 分子量: 198.308
• InChiKey: CNAWWTRDALPJDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  C-[1-(Tetrahydro-pyran-4-yl)-piperidin-4-yl]-methylamine 、 3-[2-[2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoic acid 在 N-乙基吗啉 、 O-[(ethoxycarbonyl)cyanomethyleneamino]-N,N,N',N'-tetramethyluronium tetrafluoroborate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxy-N-{[1-(oxan-4-yl)piperidin-4-yl]methyl}benzamide
  参考文献：
  名称：

  Structural Requirements for Factor Xa Inhibition by 3-Oxybenzamides with Neutral P1 Substituents:  Combining X-ray Crystallography, 3D-QSAR, and Tailored Scoring Functions

  摘要：

  The design, synthesis, and structure-activity relationship of 3-oxybenzamides as potent inhibitors of the coagulation protease factor Xa are described on the basis of X-ray structures, privileged structure motifs, and SAR information. A total of six X-ray structures of fXa/inhibitor complexes led us to identify the major protein-ligand interactions. The binding mode is characterized by a lipophilic dichlorophenyl substituent interacting with Tyr228 in the protease S1 pocket, while polar parts are accommodated in S4. This alignment in combination with docking allowed derivation of 3D-QSAR models and tailored scoring functions to rationalize biological affinity and provide guidelines for optimization. The resulting models showed good correlation coefficients and predictions of external test sets. Furthermore, they correspond to binding site topologies in terms of steric, electrostatic, and hydrophobic complementarity. Two approaches to derive tailored scoring functions combining binding site and ligand information led to predictive models with acceptable predictions of the external set. Good correlations to experimental affinities were obtained for both AFMoC (adaptation of fields for molecular comparison) and the novel TScore function. The SAR information from 3D-QSAR and tailored scoring functions agrees with all experimental data and provides guidelines and reasonable activity estimations for novel fXa inhibitors.

  DOI：

  10.1021/jm049187l

文献信息

• Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours
  申请人：——

  公开号：US20040038858A1

  公开（公告）日：2004-02-26

  Compounds of the formula (I), in which the variables have the following meaning, D is phenyl or pyridyl, each of which is unsubstituted or monosubstituted or polysubstituted by Hal, A, OR 2 , N(R 2 ) 2 , NO 2 , CN, COOR 2 or CON(R 2 ) 2 ; R 1 is H, Ar, Het, cycloalkyl or A, which may be substituted by OR 2 , SR 2 , N(R 2 ) 2 , Ar, Het, cycloalkyl, CN, COOR 2 or CON(R 2 ) 2 ; R 2 is H or A; E is phenylene, which may be monosubstituted or polysubstituted by Hal, A, OR 2 , N(R 2 ) 2 , NO 2 , CN, COOR 2 or CON(R 2 ) 2 , or is piperidine-1,4-diyl; W is AR, Het or N(R 2 ) 2 and, if E=piperidine-1,4-diyl, is alternatively R 2 or cycloalkyl, X is NH or O, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.

  公式（I）的化合物，其中变量具有以下含义，D是苯基或吡啶基，每个基团未取代或经Hal、A、OR2、N（R2）2、NO2、CN、COOR2或CON（R2）2单取代或多取代；R1为H、Ar、Het、环烷基或A，可能经OR2、SR2、N（R2）2、Ar、Het、环烷基、CN、COOR2或CON（R2）2取代；R2为H或A；E为苯基，可能经Hal、A、OR2、N（R2）2、 、CN、COOR2或CON（R2）2单取代或多取代，或为哌啶-1,4-二基；W为AR、Het或N（R2）2，如果E=piperidine-1,4-diyl，则为R2或环烷基，X为NH或O，是凝血因子Xa的抑制剂，可用于预防和/或治疗血栓栓塞性疾病和肿瘤的治疗。
• Carboxamide derivatives
  申请人：Dorsch Dieter

  公开号：US20050137230A1

  公开（公告）日：2005-06-23

  Novel compounds of the formula I in which R 1 , D, E, W, X and n are as defined in claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.

  公式I的新化合物，其中R1、D、E、W、X和n如权利要求1所定义，是凝血因子Xa的抑制剂，可用于预防和/或治疗血栓栓塞性疾病和肿瘤的治疗。
• HETERO RING COMPOUND
  申请人：Astellas Pharma Inc.

  公开号：EP2604601A1

  公开（公告）日：2013-06-19

  [Problem] A novel and excellent compound which is useful as an agent for preventing and/or treating rejection reactions in various organ transplantations, allergy diseases, autoimmune diseases, and hematologic tumor, and based on a PI3Kδ selective inhibitory action and/or an IL-2 production inhibitory action and/or a B cell proliferation inhibitory action (including an activation inhibitory action). [Means for Solution] The present inventors have investigated a compound having a PI3Kδ selective inhibitory action and/or an IL-2 production inhibitory action and/or a B cell proliferation inhibitory action (including an activation inhibitory action), and have found that the heterocyclic compound of the present invention has a PI3Kδ selective inhibitory action and/or and IL-2 production inhibitory action and/or a B cell proliferation inhibitory action (including an activation inhibitory action), thereby completing the present invention.

  问题 一种新型优良化合物，可作为预防和/或治疗各种器官移植、过敏性疾病、自身免疫性疾病和血液肿瘤中排异反应的药物，该化合物基于PI3Kδ选择性抑制作用和/或IL-2产生抑制作用和/或B细胞增殖抑制作用（包括活化抑制作用）。 [解决方法］ 本发明人研究了一种具有PI3Kδ选择性抑制作用和/或IL-2产生抑制作用和/或B细胞增殖抑制作用（包括活化抑制作用）的化合物，发现本发明的杂环化合物具有PI3Kδ选择性抑制作用和/或IL-2产生抑制作用和/或B细胞增殖抑制作用（包括活化抑制作用），从而完成了本发明。
• N-(PHENYLSULFONYL)BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS
  申请人：The Regents of The University of Michigan

  公开号：EP3494115B1

  公开（公告）日：2020-10-21
• N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS
  申请人：The Regents of The University of Michigan

  公开号：EP3569601B1

  公开（公告）日：2022-06-22